-
Je něco špatně v tomto záznamu ?
Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents
A. Attarbaschi, E. Carraro, O. Abla, S. Barzilai-Birenboim, S. Bomken, L. Brugieres, E. Bubanska, B. Burkhardt, AK. Chiang, M. Csoka, A. Fedorova, J. Jazbec, E. Kabickova, Z. Krenova, J. Lazic, J. Loeffen, G. Mann, F. Niggli, N. Miakova, T....
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, multicentrická studie
NLK
Directory of Open Access Journals
od 1994
Free Medical Journals
od 1994
Freely Accessible Science Journals
od 1994
PubMed Central
od 2009
Europe PubMed Central
od 2009
Open Access Digital Library
od 1994-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1996
- MeSH
- dítě MeSH
- Kaplanův-Meierův odhad MeSH
- kojenec MeSH
- kombinovaná terapie MeSH
- komorbidita * MeSH
- lidé MeSH
- mladiství MeSH
- náchylnost k nemoci * MeSH
- nehodgkinský lymfom diagnóza epidemiologie mortalita terapie MeSH
- novorozenec MeSH
- ochrana veřejného zdraví * MeSH
- předškolní dítě MeSH
- progrese nemoci MeSH
- recidiva MeSH
- sekundární malignity epidemiologie etiologie MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
Children and adolescents with pre-existing conditions such as DNA repair defects or other primary immunodeficiencies have an increased risk of non-Hodgkin lymphoma. However, large-scale data on patients with non-Hodgkin lymphoma and their entire spectrum of pre-existing conditions are scarce. A retrospective multinational study was conducted by means of questionnaires sent out to the national study groups or centers, by the two largest consortia in childhood non-Hodgkin lymphoma, the European Intergroup for Childhood non-Hodgkin Lymphoma, and the international Berlin-Frankfurt-Münster Study Group. The study identified 213 patients with non-Hodgkin lymphoma and a pre-existing condition. Four subcategories were established: a) cancer predisposition syndromes (n=124, 58%); b) primary immunodeficiencies not further specified (n=27, 13%); c) genetic diseases with no increased cancer risk (n=40, 19%); and d) non-classifiable conditions (n=22, 10%). Seventy-nine of 124 (64%) cancer predispositions were reported in groups with more than 20 patients: ataxia telangiectasia (n=32), Nijmegen breakage syndrome (n=26), constitutional mismatch repair deficiency (n=21). For the 151 patients with a known cancer risk, 5-year event-free survival and overall survival rates were 40%±4% and 51%±4%, respectively. Five-year cumulative incidences of progression/relapse and treatment-related death as a first event were 22%±4% and 24%±4%, respectively. Ten-year incidence of second malignancy was 24%±5% and 7-year overall survival of the 21 patients with a second malignancy was 41%±11%. Patients with non-Hodgkin lymphoma and pre-existing conditions have an inferior survival rate with a large proportion of therapy-related deaths compared to patients with non-Hodgkin lymphoma and no pre-existing conditions. They may require special vigilance when receiving standard or modified/reduced-intensity chemotherapy or when undergoing allogeneic stem cell transplantation.
Belarusian Research Center for Pediatric Oncology Hematology and Immunology Minsk Belarus
Bone Marrow Transplantation and Pediatric Hematology and Oncology Wroclaw Medical University Poland
Children's Cancer Center National Center for Child Health and Development Tokyo Japan
Department of Pediatric Oncology Institute Gustave Roussy Villejuif France
Division of Pediatrics Hematology and Oncology University Medical Center Ljubljana Slovenia
Northern Institute for Cancer Research Newcastle University UK
Pediatric Hematology and Oncology Erasmus MC Sophia Children's Hospital Rotterdam the Netherlands
Pediatric Hematology and Oncology Justus Liebig University Giessen Germany
Pediatric Hematology and Oncology Semmelweis University Budapest Hungary
Pediatric Hematology and Oncology St Anna Children's Hospital Medical University of Vienna Austria
Pediatric Hematology and Oncology University Hospital Brno Czech Republic
Pediatric Hematology and Oncology University Hospital Zurich Switzerland
Pediatric Hematology and Oncology University Hospitals Leuven Belgium
Pediatric Hematology and Oncology University of Munster Germany
Pediatric Hematology and Oncology University of Padova Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031512
- 003
- CZ-PrNML
- 005
- 20171025125423.0
- 007
- ta
- 008
- 171025s2016 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3324/haematol.2016.147116 $2 doi
- 035 __
- $a (PubMed)27515251
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Attarbaschi, Andishe $u Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Austria andishe.attarbaschi@stanna.at. $7 gn_A_00009851
- 245 10
- $a Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents / $c A. Attarbaschi, E. Carraro, O. Abla, S. Barzilai-Birenboim, S. Bomken, L. Brugieres, E. Bubanska, B. Burkhardt, AK. Chiang, M. Csoka, A. Fedorova, J. Jazbec, E. Kabickova, Z. Krenova, J. Lazic, J. Loeffen, G. Mann, F. Niggli, N. Miakova, T. Osumi, L. Ronceray, A. Uyttebroeck, D. Williams, W. Woessmann, G. Wrobel, M. Pillon, . ,
- 520 9_
- $a Children and adolescents with pre-existing conditions such as DNA repair defects or other primary immunodeficiencies have an increased risk of non-Hodgkin lymphoma. However, large-scale data on patients with non-Hodgkin lymphoma and their entire spectrum of pre-existing conditions are scarce. A retrospective multinational study was conducted by means of questionnaires sent out to the national study groups or centers, by the two largest consortia in childhood non-Hodgkin lymphoma, the European Intergroup for Childhood non-Hodgkin Lymphoma, and the international Berlin-Frankfurt-Münster Study Group. The study identified 213 patients with non-Hodgkin lymphoma and a pre-existing condition. Four subcategories were established: a) cancer predisposition syndromes (n=124, 58%); b) primary immunodeficiencies not further specified (n=27, 13%); c) genetic diseases with no increased cancer risk (n=40, 19%); and d) non-classifiable conditions (n=22, 10%). Seventy-nine of 124 (64%) cancer predispositions were reported in groups with more than 20 patients: ataxia telangiectasia (n=32), Nijmegen breakage syndrome (n=26), constitutional mismatch repair deficiency (n=21). For the 151 patients with a known cancer risk, 5-year event-free survival and overall survival rates were 40%±4% and 51%±4%, respectively. Five-year cumulative incidences of progression/relapse and treatment-related death as a first event were 22%±4% and 24%±4%, respectively. Ten-year incidence of second malignancy was 24%±5% and 7-year overall survival of the 21 patients with a second malignancy was 41%±11%. Patients with non-Hodgkin lymphoma and pre-existing conditions have an inferior survival rate with a large proportion of therapy-related deaths compared to patients with non-Hodgkin lymphoma and no pre-existing conditions. They may require special vigilance when receiving standard or modified/reduced-intensity chemotherapy or when undergoing allogeneic stem cell transplantation.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 12
- $a komorbidita $7 D015897
- 650 _2
- $a progrese nemoci $7 D018450
- 650 12
- $a náchylnost k nemoci $7 D004198
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a nehodgkinský lymfom $x diagnóza $x epidemiologie $x mortalita $x terapie $7 D008228
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a sekundární malignity $x epidemiologie $x etiologie $7 D016609
- 650 12
- $a ochrana veřejného zdraví $7 D062486
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Carraro, Elisa $u Pediatric Hematology and Oncology, University of Padova, Italy.
- 700 1_
- $a Abla, Oussama $u Depar tment of Pediatrics, Division of Hematology and Oncology, Hospital for Sick, Children, Toronto, Canada. $7 gn_A_00000621
- 700 1_
- $a Barzilai-Birenboim, Shlomit $u Pediatric Hematology and Oncology, Schneider Children's, Medical Center of Israel, Petah-Tivka, Israel and Sackler Faculty of Medicine, Tel Aviv, University, Israel.
- 700 1_
- $a Bomken, Simon $u Northern Institute for Cancer Research, Newcastle University, UK.
- 700 1_
- $a Brugieres, Laurence $u Department of Pediatric Oncology, Institute Gustave-Roussy, Villejuif, France.
- 700 1_
- $a Bubanska, Eva $u Department of Pediatric Oncology and Hematology, University Children's Hospital, Banska Bystrica, Slovakia.
- 700 1_
- $a Burkhardt, Birgit $u Pediatric Hematology and Oncology, University of Munster, Germany.
- 700 1_
- $a Chiang, Alan K S $u Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
- 700 1_
- $a Csoka, Monika $u Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary.
- 700 1_
- $a Fedorova, Alina $u Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
- 700 1_
- $a Jazbec, Janez $u Division of Pediatrics, Hematology and Oncology, University Medical Center Ljubljana, Slovenia.
- 700 1_
- $a Kabickova, Edita $u Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Krenova, Zdenka $u Pediatric Hematology and Oncology, University Hospital, Brno, Czech Republic.
- 700 1_
- $a Lazic, Jelena $u Pediatric Hematology and Oncology, University Children's Hospital, School of Medicine University of Belgrade, Serbia.
- 700 1_
- $a Loeffen, Jan $u Pediatric Hematology and Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, the Netherlands.
- 700 1_
- $a Mann, Georg $u Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Austria.
- 700 1_
- $a Niggli, Felix $u Pediatric Hematology and Oncology, University Hospital, Zurich, Switzerland.
- 700 1_
- $a Miakova, Natalia $u Pediatric Hematology and Oncology, Federal Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
- 700 1_
- $a Osumi, Tomoo $u Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
- 700 1_
- $a Ronceray, Leila $u Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Austria.
- 700 1_
- $a Uyttebroeck, Anne $u Pediatric Hematology and Oncology, University Hospitals Leuven, Belgium.
- 700 1_
- $a Williams, Denise $u Pediatric Hematology and Oncology, Cambridge University Hospitals Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
- 700 1_
- $a Woessmann, Wilhelm $u Pediatric Hematology and Oncology, Justus Liebig University, Giessen, Germany.
- 700 1_
- $a Wrobel, Grazyna $u Bone Marrow Transplantation and Pediatric Hematology and Oncology, Wroclaw Medical University, Poland.
- 700 1_
- $a Pillon, Marta $u Pediatric Hematology and Oncology, University of Padova, Italy.
- 700 1_
- $a ,
- 773 0_
- $w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 101, č. 12 (2016), s. 1581-1591
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27515251 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171025125506 $b ABA008
- 999 __
- $a ok $b bmc $g 1255105 $s 992539
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 101 $c 12 $d 1581-1591 $e 20160811 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
- LZP __
- $a Pubmed-20171025
